Picture [iito] Männer Ballett 650x80px
Organisation › Details

TiGenix N.V. (Euronext + Nasdaq: TIG)

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). *


Period Start 2003-10-01 existent
  Group Takeda (Group)
Products Industry BIOTECH
  Industry 2 cell therapy
Persons Person Bravo, Eduardo (Nordic Nanovector 201807– CEO before TiGenix + Cellerix + Sanofi-Aventis + SKB)
  Person 2 D’Augusta, Claudia (TiGenix 201204 CFO)
Region Region Leuven (Louvain)
  Country Belgium
  Street 12/2 Romeinse Straat
  City 3001 Leuven
    Address record changed: 2011-12-20
Basic data Employees C: 51 to 100 (2017-12-31)
  Currency EUR
  Annual sales 906,000 (income, operating, total, consolidated (2017) 2017-12-31)
  Profit -74,826,000 (2017-12-31)
  Cash 34,063,000 (2017-12-31)
    * Document for �About Section�: TiGenix N.V.. (4/10/12). "Press Release: TiGenix Appoints Dr. Guido Schopen as Vice President Commercial Operations". Leuven.
Record changed: 2019-11-09


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Takeda (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top